Who
Nishan M. DeSilva
Director
Company insider
Files Form 4 as: Director, Cartesian Therapeutics; VP, Finance & Strategy and CFO, Ligand Pharmaceuticals; Director, Allos Therapeutics; Director, Talon Therapeutics.
In numbers
- Trades disclosed
- 50
- Buys
- 2
- Sells
- 4
- Bought
- $24K
- Sold
- $5.9M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 30 Jul 2010
- Last trade
- 2 Jan 2026
- Last filed
- 6 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,600 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,800 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,800 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,600 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,800 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,600 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —228,000 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Code A | —178,000 at $0.00 | filing |
| 13 Nov 2023filed 15 Nov 2023 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —80,000 | filing |
| 13 Nov 2023filed 15 Nov 2023 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,000 | filing |
| 13 Nov 2023filed 15 Nov 2023 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | $70K75,000 at $0.93 | filing |
| 2 Jan 2023filed 4 Jan 2023 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 3 Jan 2022filed 5 Jan 2022 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 2 Dec 2021filed 6 Dec 2021 | RNAC Cartesian TherapeuticsBiotechnology | SEC FORM 4 Bought | $21K7,000 at $2.96 | filing |
| 23 Jun 2021filed 9 Jul 2021 | RNAC Cartesian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 14 May 2015filed 14 May 2015 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $1.6M20,938 at $74.42 | filing |
| 14 May 2015filed 14 May 2015 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.8M20,938 at $83.84 | filing |
| 14 May 2015filed 14 May 2015 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,938 at $0.00 | filing |
| 13 May 2015filed 14 May 2015 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $266K12,148 at $21.92 | filing |
| 13 May 2015filed 14 May 2015 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.0M12,148 at $83.23 | filing |
News
Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Ligand Pharmaceuticals (NASDAQ:LGND)LGND · tickerreport.com · 23 Oct 2026
0 headlines in the last 90 days name Nishan M. DeSilva; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.